Effects of pathogenic CNVs on biochemical markers: a study on the UK Biobank

Matthew Bracher-Smith, Kimberley M Kendall, Elliott Rees, Mark Einon, Michael C O'Donovan, Michael J Owen, George Kirov*

MRC Centre for Neuropsychiatric Genetics & Genomics, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University, School of Medicine, Hadyn Ellis Building, Maindy Road, Cardiff, CF24 4HQ, United Kingdom

* Corresponding author, kirov@cardiff.ac.uk; +442920688465

ABSTRACT

Background. Pathogenic copy number variants (CNVs) increase risk for medical disorders, even among carriers free from neurodevelopmental disorders. The UK Biobank recruited half a million adults who provided samples for biochemical and haematology tests which have recently been released. We wanted to assess how the presence of pathogenic CNVs affects these biochemical test results.

Methods. We called all CNVs from the Affymetrix microarrays and selected a set of 54 CNVs implicated as pathogenic (including their reciprocal deletions/duplications) and present in five or more persons. We used linear regression analysis to establish their association with 28 biochemical and 23 haematology tests.

Results. We analysed 421k participants who passed our CNV quality control filters and self-reported as white British or Irish descent. There were 268 associations between CNVs and biomarkers that were significant at a false discovery rate of 0.05. Deletions at 16p11.2 had the highest number of significant associations, but several rare CNVs had higher effect sizes indicating that the lack of significance was likely due to the reduced statistical power for rarer events. The distribution of values can be visualised on our interactive website: http://kirov.psycm.cf.ac.uk/.

Conclusions. Carriers of many pathogenic CNVs have changes in biochemical and haematology tests, and many of those are associated with adverse health consequences. These changes did not always correlate with increases in diagnosed medical disorders in this population. Carriers should have regular blood tests in order to identify and treat adverse medical consequences early. Levels of cholesterol and related lipids were unexpectedly lower

in carriers of CNVs associated with increased weight gain, most likely due to the use of statins by such people.

INTRODUCTION

Large copy number variants (CNVs) have been shown to have significant effects on common medical disorders even among the relatively healthy individuals, with no early-onset neurodevelopmental disorders, taking part in the UK Biobank (Crawford et al, 2018). Such carriers also tended to have changes in physical traits, such as weight, height, body fat content, pulse rate and blood pressure (Owen et al, 2018).

Participants in the UK Biobank agreed to donate blood, saliva and urine samples for biochemical tests at the point of their recruitment. Biochemical and haematology tests were performed on the full set of Biobank participants and the data was recently released. We expected that there will be significant changes in the levels of many of these tests among carriers of pathogenic CNVs, in line with the increased morbidity and mortality and changes in the physical traits in this population.

METHODS

Approval for the study was obtained from the UK Biobank under project 14421: "Identifying the spectrum of biomedical traits in adults with pathogenic copy number variants (CNVs)".

Participants: The UK Biobank recruited just over half a million people from the UK general population. We restricted analysis to individuals who self-reported as White British or Irish descent and whose samples passed our standard CNV QC filters (genotyping call rate < 0.96, > 30 CNVs per person, a waviness factor of < -0.03 & > 0.03 & LRR standard deviation of > 0.35).

Choice of CNVs: We tested 54 CNVs that have been proposed to be pathogenic and were carried by at least five participants (the choice of the CNVs, their chromosomal positions and details of analysis are given in our previous publications (Crawford et al, 2018, Owen et al, 2018). Briefly, the CNVs follow the lists of Coe et al (2013) and Dittwald et al (2014).

Tests: We analysed these CNVs for association with a set of 28 biomarkers and 23 haematology tests that were available for the majority of participants (Table 1). Details on the tests and methods used for their measurements are presented on the Biobank website: biobank.ctsu.ox.ac.uk/showcase/showcase/docs/serum_biochemistry.pdf, and biobank.ctsu.ox.ac.uk/showcase/showcase/docs/haematology.pdf. Between 401k and 319k people who passed our QC filters for CNVs had valid results for the tests (**Table 1**). Two of the available tests, Oestradiol and Rheumatoid Factor, were only performed on around 76k and 41k individuals, and were therefore excluded as they provided inadequate samples size for analysis of most rare CNVs.

Statistical analysis: The tested variables followed normal distributions and did not require transformation prior to analysis. We show the results in non-normalised (original) units, to allow clinicians to relate them more easily to known tests (e.g. mmol/L, U/L). Linear regression analysis was performed with sex and age as co-variates. Other potential confounders were not included, as it is not known whether confounding factors lead to the abnormalities, or are a direct consequence of the presence of a CNV. For example, we previously showed that carrying a CNV from this list has strong adverse effects on measures of social deprivation, occupation and education (Kendall et al 2019), which are also factors that could be perceived as contributing to some biochemical tests results abnormalities. In previous work (Crawford et al, 2018) we also observed practically no effect from controlling for principal components, as should be expected for genetic variants whose frequencies are

determined by selection pressure and mutation rates, rather than genetic drift (Rees et al, 2011). We used the Benjamini-Hochberg false-discovery rate (FDR) method to estimate the project-wide statistical significance (Benjamini and Hochberg 1995). A conservative false discovery rate (FDR) of 0.05 was accepted as our significance threshold (Supplementary Tables 1 and 2).

RESULTS

The comparisons of 54 CNVs and 51 tests produced 2751 associations, of which 268 were significant at FDR=0.05 (marked in bold in Supplementary Tables 1 and 2). All results are also displayed on our institutional website (http://kirov.psycm.cf.ac.uk/) where they will be updated when required. The website allows an interactive examination of the distribution of results, including those for physical traits (e.g. weight and height). **Table 2** summarises the statistically significant findings. Deletions at 16p11.2 (110 carriers) produced the largest number of statistically significant associations, followed by carriers of 15q11.2 deletions, 16p11.2 distal deletions, 15q13.3 deletions and duplications and 17q12 deletions, with 15 or 16 significant associations each. **Figure 1** is as an example of the spread of test values for the top three results for 16p11.2 deletions. A substantial proportion of carriers of this CNV have abnormal results for these three tests (ranging between 18% and 44%).

Figure 1 about here

Several rarer CNVs had even larger average differences compared to controls (in terms of standard deviations), which did not always reach significance, very likely due to the smaller sample sizes. The most pathogenic ones appear to be some of the rarest CNVs, with 5-10 carriers each: 17q12 deletions (Renal Cysts and Diabetes syndrome), 17p11.2 duplications

(Potocki-Lupski syndrome), 3q29 deletions and duplications, 22q11.2 classic and distal deletions, 15q24 duplications and 10q23 duplications.

Some of the well-established medical consequences of CNVs were associated with corresponding abnormalities in biochemical tests. For example 17q12 deletions (Renal Cysts and Diabetes syndrome) were associated with increased levels of creatinine, urea, Cystatin-C and glucose; 22q11.2 deletion carriers exhibited reduced calcium levels; 16p11.2 deletion carriers had the expected multiple abnormalities associated with cardiometabolic disorders shown for this condition; and 16p12.1 deletion carriers, who have high rates of renal failure and heart disease, have abnormalities in creatinine and Cystatin-C (**Table 2**). Other abnormalities were more subtle and would have escaped detection, if they had not been analysed in such a large dataset. Most notable are the many changes detected among carriers of 15q11.2 deletions, a CNV with neurodevelopmental phenotypes, but no confirmed medical co-morbidities. The changes were subtle (around 0.1 SD for the significant results and 0.05 SD overall) and therefore unlikely to result in significant increases of overt medical disorders. As an example, 23.7% of carriers had increased levels of Cystatin-C, compared to 18% of non-carriers. However, the abnormalities might manifest with problems in later life and reduce life expectancy if left untreated.

Most but not all significant changes suggest deterioration of function, as follows: **Liver**: Nearly all significant changes affecting liver function test (except bilirubin levels) were in the direction of higher levels, indicating liver abnormalities. **Bone**: All significant results for the three tests connected with bone function were adversely changed - reduced Vitamin D and Calcium, raised ALP. **Diabetes**: All significant changes were in the direction of raised glucose and HbA1c. **Renal**: All significant Cystatin-C results (in 14 CNVs) were increased,

as were nearly all significant urea and uric acid levels, suggesting reduced renal function in several CNVs. There were exceptions: 17p12 duplications (causing Charcot-Marie-Tooth disease type 1A) and 16p11.2 deletion carriers had reduced creatinine levels. **Cancer markers**: There were very few significant results, with mixed effects. It is difficult to interpret these as a group, as they are relevant for specific cancers. **Haematology**: Apart from general trends for increases in neutrophil and lymphocyte counts, there were no clear patterns. Several CNVs showed changes predominantly in haematological test results (as opposed to biochemistry results): 13q12.12 and 15q13.3 deletions and duplications, 15q11q13_BP3_BP5 duplications, 16p11.2 distal duplications, 17q11.2 (NF1) deletions, 7q11.23 distal duplications and TAR deletions. **Cardiovascular**: Results from several tests were deemed uninformative in this population, (most likely due to statins intake, as explained in the Discussion).

Homozygous deletions at 2q13del locus affect the gene NPHP1 and are known to cause the kidney disorder *juvenile nephronophthisis*. Three homozygous individuals were excluded from analysis, as we have reported previously that all three had renal failure (Crawford et al, 2018). Heterozygous individuals have subtle phenotypes, with changes in cholesterol and total protein (reductions) and increases in direct bilirubin. Creatinine was also increased but the evidence for association was weak after correction for multiple testing, with a change of less than 1 mcmol/L.

Mirror-image phenotypes, as reported for physical traits in our previous work (Owen et al, 2018) were rare, almost entirely confined to 16p11.2 (creatinine, platelet count and SHBG) and for 15q13.3 (MCH, MCV and MRV).

DISCUSSION

Most pathogenic CNVs tested in this study are known to increase risk for neurodevelopmental disorders and common medical phenotypes. As such it is not surprising that they are also associated with abnormal biochemical tests. About 10% of all possible CNV/test associations were significant at a conservative FDR = 0.05, suggesting multiple effects. While most are expected, e.g. high creatinine and Cystatin-C for CNVs associated with renal failure, others suggest more subtle effects that could affect medical outcomes and all-cause mortality, some of which have so far not been demonstrated. Indeed, we previously showed that carriers of 11 of these CNVs have statistically significant increase in mortality, which was not fully explained by the statistically significant associated medical conditions (Crawford et al, 2018).

One set of associations runs against the expected directions and deserves a further discussion: Cholesterol and associated biochemical tests (LDL, HDL, ApoA1 and ApoB) were *reduced* (rather than increased) among carriers of CNVs that are associated with obesity or ischaemic heart disease, such as 16p12.1 deletions, 16p11.2 deletions and 16p11.2 distal deletions (Bochukova et al, 2010, Crawford et al, 2018). We suspect that this is due to a large proportion of such patients taking statins, precisely because they are overweight or have cardiovascular problems. This possibility is confirmed by an extreme example: people diagnosed with “high cholesterol” in the sample as a whole, also showed significantly reduced levels of these tests, a seemingly counter-intuitive finding. Levels of cholesterol were, on average, 0.66 mmol/L lower among the 70,052 people who had this diagnosis, a situation only likely if statins were taken after the diagnosis was made (**Table 3**). This class of medicines is highly effective in lowering cholesterol and lipid concentrations (Cholesterol treatment trialists, 2019). At the point of recruitment the participants listed the medications

they were taking, so we tested whether reductions in cholesterol were present only among those on statins. This could not fully explain the observations. Even CNV carriers who had not declared statins intake had lower cholesterol levels than non-carriers who were not taking statins. In a linear regression analysis, being on statins was associated with a 1.61 mmol/L lower cholesterol for the population as a whole, while a diagnosis of "high cholesterol" was associated with only 0.4 mmol/L higher cholesterol. Similar analysis on 16p11.2 deletion carriers showed that being on statins was associated with a 1.34 mmol/L lower cholesterol, while carrying the deletion was associated with 0.19 mmol/L lower cholesterol. We suggest that the only way to reconcile these findings is that a proportion of people (CNV carriers and non-carriers) had either taken statins at an earlier time, or had not declared them. CNV carriers who are obese or have cardiovascular incidents could be more likely to have been prescribed statins. A separate analysis of all biochemical results with statins intake as a co-variate are presented in **Supplementary Table 2**. Researchers should be aware of potential bias in the UK Biobank when interpreting findings on cholesterol and other lipids, a problem which could be reduced once the primary care (GP) data become available.

CONCLUSIONS

Our findings of changes in biochemical tests extend our previous reports on this population, showing adverse changes in basic physical characteristics in CNV carriers (Owen et al, 2018) and higher rates of common medical disorders (Crawford et al, 2018). This strengthens the case for general monitoring of such carriers and treatment and prevention of biochemical abnormalities, such as with statins or antidiabetic drugs. As an example, 43% of carriers of 16p11.2 deletions have levels of HbA1c above the normal range of 40 mmol/mol, compared to 12.7% of CNV non-carriers (**Figure 1**). The findings of this study cannot yet be used for

analysis of cholesterol and related lipids, due to the high rates of statins intake in this population. Clinicians involved in the care of CNV carriers will be able to examine the results in more detail, using our interactive website which shows the distribution of values between carriers and non-carriers, separately for men and women: http://kirov.psycm.cf.ac.uk/.

Acknowledgements. This research has been conducted using the UK Biobank Resource under Application Number 14421.

Conflict of interest statement. The work at Cardiff University was funded by the Medical Research Council (MRC) Centre Grant (MR/L010305/1) and Program Grant (G0800509).

Legends to Tables and Figures:

Table 1. List of biochemical and haematological tests, their ranges and the number of people with valid results. The "Function" that the tests measure is listed according to the UK Biobank website.

Table 2. CNVs analysed and the associated biochemical tests and medical conditions (as presented in Crawford et al, 2018). An * denotes cholesterol and related lipid levels that are unexpectedly reduced in carriers of CNVs associated with increased BMI.

Table 3. Cholesterol levels in cases and controls, according to statins intake, diagnosis of "high cholesterol" and presence of a 16p11.2 deletion, an example of a CNV highly associated with obesity and cardiometabolic disorders.

Figure 1. Spread of the values of the top three findings for 16p11.2 deletions and controls: a) HbA1c. Normal levels of HbA1c are ≤40mmol/mol, leaving 43% of CNV carriers with increased levels. b) Cystatin-C. Normal levels for Cystatin C are ≤1.02 mg/L for people over the age of 50, leaving 44% with abnormal levels. c) Alkaline phosphatase. Normal levels for Alkaline Phosphatase are <130 U/L for adults, leaving 18% of carriers with abnormal levels.

REFERENCES

Benjamini,Y. and Hochberg,Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J. Royal. Stat. Soc. B.*, **57**, 289-300.

Bochukova,E.G., Huang,N., Keogh,J., Henning,E., Purmann,C., Blaszczyk,K., Saeed,S., Hamilton-Shield,J., Clayton-Smith,J., O'Rahilly,S. et al. (2010) Large, rare chromosomal deletions associated with severe early-onset obesity. *Nature*, **463**, 666-670.

Cholesterol Treatment Trialists' Collaboration. (2019) Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. **393**(10170):407-415.

Coe,B.P., Witherspoon,K., Rosenfeld,J.A., van Bon,B.W., Vulto-van Silfhout,A.T., Bosco,P., Friend,K.L., Baker,C., Buono,S., Vissers,L.E., et al. (2014) Refining analyses of copy number variation identifies specific genes associated with developmental delay. *Nat. Genet.*, **46**, 1063-1071.

Crawford K, Bracher-Smith M, Owen D, Kendall KM, Rees E, Pardiñas AF, Einon M, Escott-Price V, Walters JTR, O'Donovan MC, Owen MJ, Kirov G (2019). Medical consequences of pathogenic CNVs in adults: Analysis of the UK Biobank. *J Med Genet*. **56,** 131-138.

Dittwald,P., Gambin,T., Szafranski,P., Li,J., Amato,S., Divon,M.Y., Rodríguez Rojas,L.X., Elton,L.E., Scott,D.A., Schaaf,C.P., et al. (2013) NAHR-mediated copy-number variants in a clinical population: mechanistic insights into both genomic disorders and Mendelizing traits. *Genome. Res.*, **23**, 1395-1409.

Kaur,Y., de Souz,R.J., Gibson,W.T. and Meyre,D. (2017) A systematic review of genetic syndromes with obesity *Obes Rev*, **18**, 603–634.

Kendall K, Bracher-Smith M, Fitzpatrick H, Lynham A, Rees E, Escott-Price V, Owen MJ, O'Donovan M, Walters JTR, Kirov G (2019). Cognitive performance and functional outcomes of carriers of pathogenic CNVs: Analysis of the UK Biobank. *Brit J Psychiatry*, **214**, 297–304.

Owen D, Bracher-Smith M, Kendall KM, Rees E, Einon M, Escott-Price V, Owen MJ, O'Donovan MC, Kirov G (2018). Effects of pathogenic CNVs on physical traits in participants of the UK Biobank. *BMC Genomics*. Dec 4;19(1):867.

Rees E, Moskvina V, Owen MJ, O'Donovan MC, Kirov G. De Novo Rates and Selection of Schizophrenia-Associated Copy Number Variants. *Biol Psychiatry*. 2011, **70**, 1109-1114.

CNV	SD of mean difference	N CNV carriers	N sign. results	Sign. associated tests	Sign. associated medical phenotypes
10q11.21q11.23del	0.1323	57			
10q11.21q11.23dup	0.0998	41			
10q23dup	0.4658	7			
13q12.12del	0.0786	85	4	WBC and lymphocyte number, reticulocyte number and %	
13q12.12dup	0.0628	236	2	reticulocyte number and %	
13q12del_CRYL1	0.0348	379	1	RBC	
13q12dup_CRYL1	0.2401	10	1	Monocyte number and %	
15q11.2del	0.0533	1664	15	APOA1*, Creatinine, Cys-C, Direct bilirubin, HDL*, IGF-1, Phosphate, Total bilirubin, Urea, Vit-D, MCV, MCH, RBC, monocyte %	
15q11.2dup	0.0174	2041	1	SHBG	
15q11q13del_BP3_BP4	0.2224	16	2	Albumin, CRP	gastric_reflux
15q11q13dup_BP3_BP4	0.1330	53			
15q11q13dup_BP3_BP5	0.1495	9	5	MRV, MCV, neutrophil %, RBC, lymphocyte %	
15q13.3del	0.2451	42	13	APOA1*, Glucose, HbA1c, HDL*, Triglyceride, Vit-D, RBC, MCV, MCH, neutrophil number, WBC, MRV, haematocrit	Asthma, diabetes type2
15q13.3del_CHRNA7	0.1717	10			
15q13.3dup	0.1058	240	15	ALP, CRP, Cys-C, GGT, Vit-D, MCV, MCH, lymphocyte %, RBC, MRV, neutrophil number and %, basophil number and %, monocyte number	death
15q13.3dup_CHRNA7	0.0157	3031			
15q24dup	0.4853	9	3	ALT, AST, GGT	
16p11.2del	0.4237	110	28	ALT, Albumin, ALP, APOA1*, AST, Calcium, Cholesterol*, CRP, Creatinine, Cys-C, GGT, Glucose, HbA1c, HDL*, IGF-1, SHBG, Total bilirubin, Triglyceride, Uric acid, Vit-D, platelet count, neutrophil %, MRV, WBC, monocyte %, eosinophil %	diabetes type2, obesity, anaemia, hypertension, asthma, renal failure, ostheoarthritis, respiratory, death, high cholesterol, heart failure, hernia
16p11.2distal_del	0.3724	58	16	ALT, ALP, APOA1*, AST, Cholesterol*, CRP, Cys-C, GGT, Glucose, HbA1c, HDL*, LDL*, Reticulocyte number, HGB, reticulocyte %, haematocrit	diabetes type2, obesity, gout
16p11.2distal_dup	0.1011	137	5	Total protein, lymphocyte number, WBC, platelet count, HGB	

16p11.2dup	0.1192	138	7	Creatinine, SHBG, Vit-D, platelet count, HBG, haematocrit, RBC	Irritable bowel syndrome, sciatica
16p12.1del	0.1097	246	9	Albumin, ALP, Creatinine, Cys-C, HDL*, monocyte number, RVC, MCH, MCV,	Hypertension, obesity, renal failure, diabetes type2, heart disease (not ishaemic), ureter/bladder
16p12.1dup	0.0544	202			
16p13.11del	0.0792	131	1	Lymphocyte %	
16p13.11dup	0.0709	828	12	ALP, APOA1*, APOB*, Cholesterol*, HDL*, LDL*, SHBG, Uric acid, Vit-D, HGB, MCH, basophil number	Hypertension
17p12del_HNPP	0.0653	237			neuropathies
17p12dup_CMT1A	0.1375	124	4	Albumin, Calcium, Creatinine, Cys-C	Neuropathies, anaemia
17q11.2del_NF1	0.2958	9	5	WBC, Monocyte, basophil and neutrophil number, basophil %	
17q12del	1.0214	9	15	ALT, ALP, AST, Creatinine, Cys-C, GGT, Glucose, HbA1c, Urea, Vit-D, WBC, lymphocyte, monocyte, neutrophil and basophil number	Diabetes type1, digestive system
17q12dup	0.2307	101	9	APOB, Cholesterol, Creatinine, Cys-C, Lopo(a), SHBG, Total protein, Urea, Uric acid	Renal failure
1q21.1del	0.0827	113	3	ALP, platelet count, lymphocyte %	Cataracts
1q21.1dup	0.1313	177	8	APOA1, Cholesterol*, Cys-C, Glucose, HbA1c, HDL*, monocyte number and %	Diabetes type2
22q11.2del	0.4129	10	5	Calcium, Cys-C, platelet count, MRV, lymphocyte %	
22q11.2distal_del	0.7607	5	8	Cholesterol, Cys-C, Testosterone, Urea, monocyte and basophile number and %	
22q11.2distal_dup	0.2419	13	0		
22q11.2dup	0.0967	280	11	Albumin, Cys-C, Total protein, Triglyceride, Vit-D, RBC, HGB, haematocrit, platelet count, eosinophil %	Gastric reflux, hernia
2q11.2del	0.2376	31	3	Cys-C, Phosphate, MRV	
2q11.2dup	0.1375	29	2	Calcium, eosinophil number	
2q13del	0.2135	53	4	CRP, Cys-C, IGF-1, SHBG	
2q13del_NPHP1	0.0296	2448	4	Cholesterol, Direct bilirubin, LDL, Total protein	
2q13dup	0.1492	71	4	ALT, AST, HbA1c, neutrophil number	

2q13dup_NPHP1	0.0185	1976			
2q21.1del	0.1150	41			
2q21.1dup	0.0893	59			
3q29del	0.6042	9	8	ALT, APOB, GGT, Glucose, HbA1c, Glucose, MCH, MCV, RBC,	
3q29dup	0.5964	5	4	Glucose, WBC, lymphocyte number and %	Cancer, diverticular disease of intestine, inflammatory bowel disease, renal failure
7q11.23dup_distal	0.1688	24	3	RBC, HBG, haematocrit	
8p23.1dup	0.2359	6			
NRXN1del	0.1254	163	5	Albumin, HDL*, Phosphate, Total bilirubin, Triglyceride*	Aneurisms
Potocki_Lupski	0.4313	5	2	Albumin, Total protein	
PWS_dup	0.2946	19	1	Calcium	
TAR_del	0.1469	75	8	Albumin, Uric acid, MCV, MRV, reticulocyte number, RBC, MCR, reticulocyte %	
TAR_dup	0.0833	436	6	ALP, APOA1*, Cholesterol*, HbA1c, HDL*, Uric acid	obesity
WBS_dup	0.3730	14	5	Albumin, ALP, CRP, Uric acid, MCV	

Table 1

Test	Function	N people	Mean	Min	Max	Std. Dev.	Unit
Alanine aminotransferase (ALT)	Liver	401476	23.56	3.01	495.19	14.15	U/L
Albumin	Liver	367822	45.22	18.87	59.80	2.61	g/L
Aspartate aminotransferase (AST)	Liver	400150	26.22	3.30	947.20	10.54	U/L
Direct bilirubin	Liver	341413	1.83	1.00	70.06	0.85	mcmol/L
Gamma glutamyltransferase (GGT)	Liver	401418	37.45	5.00	1184.90	42.18	U/L
Total bilirubin	Liver	399948	9.13	1.08	144.52	4.42	mcmol/L
Alkaline phosphatase (ALP)	Bone and joint	401640	83.73	8.00	1416.7	26.53	U/L
Vitamin D	Bone and joint	383994	49.67	10.00	340.00	20.98	nmol/L
Calcium	Bone and joint	367686	2.38	1.05	3.57	0.09	mmol/L
Apolipoprotein A1 (APOA1)	Cardiovascular	365618	1.54	0.42	2.50	0.27	g/L
Apolipoprotein B (APOB)	Cardiovascular	399665	1.03	0.40	2.00	0.24	g/L
Cholesterol	Cardiovascular	401615	5.71	0.60	15.46	1.14	mmol/L
C-reactive protein (CRP)	Cardiovascular	400753	2.60	0.08	79.96	4.38	mg/L
HDL cholesterol	Cardiovascular	367652	1.45	0.22	4.40	0.38	mmol/L
LDL cholesterol	Cardiovascular	400878	3.57	0.27	9.80	0.87	mmol/L
Lipoprotein (a)	Cardiovascular	319638	44.11	3.80	189.00	49.38	nmol/L
Triglycerides	Cardiovascular	401301	1.76	0.23	11.28	1.03	mmol/L
HbA1c	Diabetes	401566	35.97	15.00	515.2	6.52	mmol/mol
Glucose	Diabetes	367387	5.12	1.01	36.81	1.21	mmol/L
Creatinine	Renal	401421	72.29	10.80	1499.3	17.95	mcmol/L
Cystatin C	Renal	401577	0.91	0.30	7.49	0.17	mg/L
Phosphate	Renal	367125	1.16	0.37	4.70	0.16	mmol/L
Total protein	Renal	367406	72.36	36.27	117.36	4.04	g/L
Urea	Renal	401346	5.43	0.81	41.83	1.39	mmol/L
Uric acid (UA)	Renal	401135	309.39	89.10	884.30	80.41	mcmol/L
Insulin-like Growth Factor-1 (IGF-1)	Cancer	399465	21.37	1.45	126.77	5.66	nmol/L
Sex Hormone Binding Globulin (SHBG)	Cancer	364235	51.90	0.39	241.92	27.72	nmol/L
Testosterone	Cancer	363579	6.57	0.35	54.34	6.05	nmol/L
Basophill number	haematology	407888	0.00	2.60	0.03	0.05	x 10^9 cells/L
Basophill percent	haematology	407894	0.00	33.80	0.57	0.61	percent
Eosinophill number	haematology	407888	0.00	9.60	0.17	0.14	x 10^9 cells/L
Eosinophill percent	haematology	407894	0.00	100.00	2.56	1.85	percent
Haematocrit	haematology	408607	0.05	72.48	41.12	3.52	percent
Haemoglobin concentration (HGB)	haematology	408607	0.11	22.27	14.20	1.23	g/dl
Lymphocyte number	haematology	407888	0.00	177.00	1.95	1.16	x 10^9 cells/L
Lymphocyte percent	haematology	407894	0.00	98.70	28.65	7.36	percent
Mean corpuscular volume (MCV)	haematology	408605	53.52	160.30	91.33	4.39	fL
Mean corpuscular haemoglobin (MCH)	haematology	408604	0.00	95.67	31.55	1.83	g/dL
Mean corpuscular haemoglobin concentration (MCHC)	haematology	408600	16.10	97.30	34.54	1.06	fL
Mean reticulocyte volume (MRV)	haematology	402048	46.00	249.45	105.84	7.77	fL
Monocyte number	haematology	407888	0.00	34.26	0.48	0.22	x 10^9 cells/L
Monocyte percent	haematology	407894	0.00	96.90	7.09	2.70	percent

Neutrophill number	haematology	407888	0.00	52.02	4.25	1.41	x 10^9 cells/L
Neutrophill percent	haematology	407894	0.00	97.70	61.13	8.40	percent
Nucleated red blood cell number	haematology	407878	0.00	6.90	0.00	0.03	x 10^9 cells/L
Nucleated red blood cell percent	haematology	407874	0.00	48.86	0.03	0.40	percent
Platelet count	haematology	408605	0.30	1821.0	253.44	59.89	x 10^9 cells/L
Red blood cell count	haematology	408607	0.01	7.91	4.51	0.41	x 10^{12} cells/L
Reticulocyte number	haematology	402047	0.00	2.39	0.06	0.04	x 10^{12} cells/L
Reticulocyte percent	haematology	402047	0.00	90.91	1.35	0.89	percent
White blood cell count (WBC)	haematology	408602	0.00	189.50	6.90	2.06	x 10^9 cells/L

Table 2

Group	On statins	Cholesterol mean (SD)	N participants
People with no diagnosis of “High cholesterol”	No	5.89 (1.05)	316856
	Yes	4.39 (0.89)	14707
People with a diagnosis of “High cholesterol”	No	6.38 (1.23)	19153
	Yes	4.74 (0.93)	50899
CNV non-carriers	No	5.92 (1.07)	323170
	Yes	4.66 (0.94)	63000
16p11.2del carriers	No	5.58 (1.31)	78
	Yes	4.45 (1.14)	25

Table 3


0.15
0.10
0.05
0.00
density
0
50
100
150
HbA1c
CNV_16p11.2del
controls
carriers


density
3
2
1
0
0
1
2
3
4
CysC
CNV_16p11.2del
controls
carriers


0.020
0.015
0.010
0.005
0.000
density
0
100
200
300
400
500
Alkphos
CNV_16p11.2del
controls
carriers